Wells Fargo & Co Reaffirms “Buy” Rating for Delphi Technologies (DLPH)

Share on StockTwits

Wells Fargo & Co reissued their buy rating on shares of Delphi Technologies (NYSE:DLPH) in a research note published on Wednesday.

A number of other research firms have also recently issued reports on DLPH. Morgan Stanley cut Delphi Technologies from an overweight rating to an equal weight rating and set a $30.00 target price for the company. in a research note on Monday, October 15th. Buckingham Research set a $27.00 target price on Delphi Technologies and gave the company a hold rating in a research note on Monday, October 8th. Goldman Sachs Group cut Delphi Technologies from a buy rating to a neutral rating and set a $30.00 target price for the company. in a research note on Thursday, October 11th. Bank of America raised Delphi Technologies from an underperform rating to a neutral rating and set a $36.00 target price for the company in a research note on Tuesday, October 23rd. Finally, Zacks Investment Research cut Delphi Technologies from a hold rating to a sell rating in a research note on Wednesday, October 3rd. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have given a buy rating to the company’s stock. Delphi Technologies currently has a consensus rating of Hold and an average price target of $37.50.

NYSE DLPH traded down $2.15 on Wednesday, reaching $18.13. The company had a trading volume of 3,072,381 shares, compared to its average volume of 2,256,157. The company has a market capitalization of $1.79 billion and a PE ratio of 3.52. The company has a current ratio of 1.59, a quick ratio of 1.18 and a debt-to-equity ratio of 4.68. Delphi Technologies has a 52 week low of $18.12 and a 52 week high of $60.39.

Delphi Technologies (NYSE:DLPH) last released its quarterly earnings data on Wednesday, November 7th. The company reported $0.72 EPS for the quarter, missing analysts’ consensus estimates of $0.73 by ($0.01). The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. Delphi Technologies had a net margin of 5.61% and a return on equity of 142.27%. The company’s revenue for the quarter was down 3.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.25 EPS. As a group, sell-side analysts predict that Delphi Technologies will post 4.23 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, November 14th. Shareholders of record on Tuesday, November 6th will be paid a $0.17 dividend. The ex-dividend date is Monday, November 5th. This represents a $0.68 dividend on an annualized basis and a yield of 3.75%. Delphi Technologies’s payout ratio is 13.20%.

In other news, SVP Susan M. Suver sold 1,174 shares of the company’s stock in a transaction dated Tuesday, August 21st. The stock was sold at an average price of $95.00, for a total transaction of $111,530.00. Following the completion of the transaction, the senior vice president now directly owns 62,268 shares of the company’s stock, valued at $5,915,460. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Frank J. Dellaquila acquired 750 shares of Delphi Technologies stock in a transaction dated Thursday, August 23rd. The shares were purchased at an average cost of $89.00 per share, with a total value of $66,750.00. Following the completion of the transaction, the director now directly owns 4,818 shares of the company’s stock, valued at $428,802. The disclosure for this purchase can be found here. 0.12% of the stock is owned by corporate insiders.

Several hedge funds have recently bought and sold shares of the company. Trexquant Investment LP boosted its position in shares of Delphi Technologies by 137.2% during the third quarter. Trexquant Investment LP now owns 66,202 shares of the company’s stock worth $2,076,000 after buying an additional 38,287 shares during the period. Janus Henderson Group PLC boosted its position in shares of Delphi Technologies by 22.3% during the third quarter. Janus Henderson Group PLC now owns 2,275,425 shares of the company’s stock worth $71,357,000 after buying an additional 414,550 shares during the period. Alliancebernstein L.P. boosted its position in shares of Delphi Technologies by 9.9% during the third quarter. Alliancebernstein L.P. now owns 1,670,036 shares of the company’s stock worth $52,372,000 after buying an additional 150,978 shares during the period. Quantum Capital Management boosted its position in shares of Delphi Technologies by 391.6% during the third quarter. Quantum Capital Management now owns 86,226 shares of the company’s stock worth $2,704,000 after buying an additional 68,686 shares during the period. Finally, Zeke Capital Advisors LLC acquired a new position in shares of Delphi Technologies during the third quarter worth about $759,000. 82.84% of the stock is owned by institutional investors.

About Delphi Technologies

Delphi Technologies PLC engages in the design, development, and manufacture of integrated powertrain technologies worldwide. The company operates through two segments, Powertrain Systems and Delphi Technologies Aftermarket. The Powertrain Systems segment provides fuel injection systems, as well as other powertrain products comprising valvetrain, fuel delivery modules, ignition coils, canisters, sensors, valves, and actuators; and electronic control modules with the corresponding software, algorithms, and calibration that provide centralized management of various powertrain components.

Featured Story: Bull Market

Analyst Recommendations for Delphi Technologies (NYSE:DLPH)

Receive News & Ratings for Delphi Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delphi Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.